Key result
Patients who presented a positive clinical response 6 months after cardiac resynchronization therapy showed a significantly smaller change in soluble IL-6 receptor concentration compared to nonresponders (-0.2 vs 7 ng/ml, p=0.04).
Why the study?
Does cardiac resynchronization therapy alter the IL-6 signaling system in patients with HF-REF?
Observational (n=123)
No
Does cardiac resynchronization therapy alter the IL-6 signaling system in patients with HF-REF?
Answers are grounded in this paper and cite their sources.
Clinical improvement following cardiac resynchronization therapy in HF-REF patients is associated with modulation of the IL-6 inflammatory signaling pathway.
INTRODUCTION: Increased expression of interleukin-6 (IL-6) has been described in left ventricular dysfunction in the course of chronic heart failure. Cardiac resynchronization therapy (CRT) is a unique treatment method that may reverse the course of chronic heart failure (CHF) with reduced ejection fraction (HF-REF). We aimed to evaluate the IL-6 system, including soluble IL-6 receptor (sIL-6R) and soluble glycoprotein 130 (sgp130), in HF-REF patients, with particular emphasis on CRT effects. MATERIAL AND METHODS: The study enrolled 88 stable HF-REF patients (63.6 ±11.1 years, 12 females, EF < 35%) and 35 comorbidity-matched controls (63.5 ±9.8 years, 7 females). Forty-five HF-REF patients underwent CRT device implantation and were followed up after 6 months. Serum concentrations of IL-6, sIL-6R and sgp130 were determined using ELISA kits. CONCLUSIONS: HF-REF patients present higher IL-6 and lower sIL-6R levels. IL-6 concentration reflects their clinical status. CRT-related improvement of patients' functional status is associated with a smaller change of sIL-6R concentration in time.
No takes yet. Share an insight, caveat, or question.
Ptaszyńska‐Kopczyńska et al. (2016) conducted an observational in Chronic heart failure with reduced ejection fraction (HF-REF) (n=123). Cardiac resynchronization therapy (CRT) vs. Nonresponders to CRT was evaluated on Change in soluble IL-6 receptor (sIL-6R) concentration (p=0.04). Patients who presented a positive clinical response 6 months after cardiac resynchronization therapy showed a significantly smaller change in soluble IL-6 receptor concentration compared to nonresponders (-0.2 vs 7 ng/ml, p=0.04).
Synapse has enriched 10 related papers. Consider them for comparative context: